CoChat
Sign Up
Cited by 42Ovarian cancer diagnosis and treatmentCancer therapeutics and mechanismsPARP inhibition in cancer therapy

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Krasner, Carolyn N., Campos, Susana M., Young, Chantay L., Chadda, Karan R., Lee, Hang, Birrer, Michael J., Horowitz, Neil S., Konstantinopoulos, Panagiotis A., D'Ascanio, Antonella M., Matulonis, Ursula A., Penson, Richard T.·2021·Gynecologic Oncology
DOI 10.1016/j.ygyno.2021.07.002
Open this paper in CoChat — free account

Abstract

Background Topoisomerase-1 inhibitors are an important class of cytotoxics associated with toxicity that limits their use. CRLX101 is a novel cyclodextrin-containing polymer conjugate of camptothecin (CPT) that self-assembles into nanoparticles to deliver sustained levels of active CPT into cancer cells while substantially reducing systemic exposure. Methods We conducted sequential phase II, open label, single arm clinical trials to evaluate CRLX101 as a single agent (n = 29) and with bevacizumab (Bev) (n = 34). Patients (pts) had measurable recurrent epithelial ovarian, tubal or primary peritoneal cancer, that could be platinum refractory, resistant or sensitive. Cohort A (Single agent CRLX101) allowed up to 3 prior chemotherapy regimens, but no prior topo-1 inhibitors. Pts received CRLX101 15 mg/m 2 IV every 14 days Q28 with response evaluation every 2 cycles. Cohort B also received Bev 10 mg/kg D1,15 Q28, and included only platinum resistant disease with up to 2 prior lines, and more rigorous eligibility criteria. Results CRLX101 was well tolerated other than nausea, fatigue and anemia. 29 pts. received a median of 3 (1-16) cycles with a clinical benefit rate (CBR) of 68% and overall response rate (ORR) of 11%. With the addition of Bev in Cohort B (n = 34), the CBR was increased to 95% and the ORR to 18%. PFS was 4.5 months (0.9 to 15.9 months) in Cohort A and 6.5 months (2.8 to 14.4 months) in Cohort B. Bev increased the incidence of hypertension and qualitatively increas…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2021.07.002

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a Phase II trial in ovarian cancer, CRLX101 demonstrated acceptable tolerability as monotherapy or with bevacizumab.

    “In a Phase II trial involving patients with ovarian cancer, CRLX101 demonstrated acceptable tolerability when administered either as a single agent or in combination with bevacizumab.”

    From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [332]

  • CRLX101 monotherapy achieved an overall response rate of 11%, which increased to 18% when combined with bevacizumab.

    “As monotherapy, CRLX101 achieved an overall response rate of 11%, which increased to 18% when combined with bevacizumab [332].”

    From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [332]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., & Penson, R. T.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Massachusetts General Hospital (US)
  • University of Arkansas at Little Rock (US)
Corresponding author
Penson, Richard T.
ORCID
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2021-09
Volume
162
Issue
3
Pages
661-666
ISSN
0090-8258 (ISSN-L)
DOI
10.1016/j.ygyno.2021.07.002
OpenAlex
W3178957657
Cited by
42
References
18
Citations by year
2026: 12 · 2025: 12 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 3
FWCI
3.88
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Gynecologic Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
CRLX101, camptothecin, topoisomerase I inhibitor, recurrent ovarian cancer, bevacizumab, platinum-resistant ovarian cancer, nanoparticle drug delivery, combination chemotherapy, progression-free survival, toxicity
MeSH terms
Bevacizumab, Carcinoma, Ovarian Epithelial, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cyclodextrins, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Peritoneal Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review